Hospital acquired venous thromboembolism in children with sickle cell disease

References

• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4(1):18010. doi:10.1038/nrdp.2018.10.
   PubMedGoogle Scholar
• Famodu AA, Oduwa D. Platelet count and platelet factor 3 (PF-3) availability in sickle cell disease. Br J Biomed Sci. 1995;52(4):323–324.
   PubMed Web of Science ®Google Scholar
• Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol. 1980;33(7):622–625. doi:10.1136/jcp.33.7.622.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med. 2003;115(9):721–728. doi:10.1016/j.amjmed.2003.07.011.
   PubMed Web of Science ®Google Scholar
• Westerman MP, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 1999;134(4):352–362. doi:10.1016/s0022-2143(99)90149-x.
   PubMed Web of Science ®Google Scholar
• Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica. 2009;94(11):1481–1484. doi:10.3324/haematol.2009.013672.
   PubMed Web of Science ®Google Scholar
• Srisuwananukorn A, Raslan R, Zhang X, et al. Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Adv. 2020;4(9):1978–1986. doi:10.1182/bloodadvances.2019001384.
   PubMed Web of Science ®Google Scholar
• Scarpato B, Strykowski R, Lawrence R, et al. Risk factors for venous thromboembolism and clinical outcomes in adults with sickle cell disease. Thromb Updat. 2022;6:100101. doi:10.1016/j.tru.2022.100101.
   Google Scholar
• Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443–449. doi:10.1016/j.amjmed.2012.12.016.
   PubMed Web of Science ®Google Scholar
• Brunson A, Keegan T, Mahajan A, White R, Wun T. High incidence of venous thromboembolism recurrence in patients with sickle cell disease. Am J Hematol. 2019;94(8):862–870. doi:10.1002/ajh.25508.
   PubMed Web of Science ®Google Scholar
• O'Brien SH, Stanek JR, Witmer CM, Raffini L. The continued rise of venous thromboembolism across US Children’s Hospitals. Pediatrics. 2022;149(3):e2021054649. doi:10.1542/peds.2021-054649.
   PubMed Web of Science ®Google Scholar
• Betensky M, Kumar R, Hankins JS, Goldenberg NA, Duration of Antithrombotic Therapy Working Group of the Pediatric and Neonatal Thrombosis and Haemostasis Subcommittee of the ISTH. Venous thromboembolism in pediatric patients with sickle cell disease: a North American survey on experience and management approaches of pediatric hematologists. Thromb Res. 2022;211:133–139. doi:10.1016/j.thromres.2022.01.028.
   PubMed Web of Science ®Google Scholar
• Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47(6):763–766. doi:10.1203/00006450-200006000-00013.
   PubMed Web of Science ®Google Scholar
• Humes DJ, Nordenskjöld A, Walker AJ, West J, Ludvigsson JF. Risk of venous thromboembolism in children after general surgery. J Pediatr Surg. 2015;50(11):1870–1873. doi:10.1016/j.jpedsurg.2015.05.010.
   PubMed Web of Science ®Google Scholar
• Manlhiot C, Brandão LR, Schwartz SM, et al. Management and outcomes of patients with occlusive thrombosis after pediatric cardiac surgery. J Pediatr. 2016;169:146–153. doi:10.1016/j.jpeds.2015.10.046.
   PubMed Web of Science ®Google Scholar
• Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–204. doi:10.1111/j.1538-7836.2009.03678.x.
   PubMed Web of Science ®Google Scholar
• Kumar R, Stanek J, Creary S, Dunn A, O’Brien SH. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Adv. 2018;2(3):285–291. doi:10.1182/bloodadvances.2017012336.
   PubMed Web of Science ®Google Scholar
• Raffini L, Huang Y-S, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–1008. doi:10.1542/peds.2009-0768.
   PubMed Web of Science ®Google Scholar
• Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV. Pulmonary embolism in sickle cell disease: a case–control study. J Thromb Haemost. 2012;10(5):760–766. doi:10.1111/j.1538-7836.2012.04697.x.
   PubMed Web of Science ®Google Scholar
• Austin H, Key NS, Benson JM, et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007;110(3):908–912. doi:10.1182/blood-2006-11-057604.
   PubMed Web of Science ®Google Scholar
• Mekontso Dessap A, Deux J-F, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011;184(9):1022–1029. doi:10.1164/rccm.201105-0783OC.
   PubMed Web of Science ®Google Scholar
• Bala N, Stanek J, Rodriguez V, Villella A. Prevalence and risk factors for pulmonary embolism in children with sickle cell disease: an institutional retrospective cohort study. Blood Coagul Fibrinolysis. 2023;34(5):289–294. doi:10.1097/MBC.0000000000001224.
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342(25):1855–1865. doi:10.1056/NEJM200006223422502.
   PubMed Web of Science ®Google Scholar
• Mahajerin A, Croteau SE. Epidemiology and risk assessment of pediatric venous thromboembolism. Front Pediatr. 2017;5(April):68. doi:10.3389/fped.2017.00068.
   PubMedGoogle Scholar
• Woods GM, Sharma R, Creary S, et al. Venous thromboembolism in children with sickle cell disease: a retrospective cohort study. J Pediatr. 2018;197:186–190.e1. doi:10.1016/j.jpeds.2018.01.073.
   PubMed Web of Science ®Google Scholar
• Abdul-Rauf A, Gauderer M, Chiarucci K, Berman B. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol. 1995;17(4):342–345. doi:10.1097/00043426-199511000-00011.
   PubMed Web of Science ®Google Scholar
• Davila J, Stanek J, O'Brien SH. Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients. Blood Adv. 2023;7(9):1762–1768. doi:10.1182/bloodadvances.2022007802.
   PubMed Web of Science ®Google Scholar
• Sharma R, Woods GM, Creary S, et al. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: a pilot study. Pediatr Blood Cancer. 2019;66(4):e27588. doi:10.1002/pbc.27588.
   PubMed Web of Science ®Google Scholar
• Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis. 2013;35(3):352–358. doi:10.1007/s11239-013-0895-y.
   PubMed Web of Science ®Google Scholar
• Liem RI, Lanzkron S, Coates TD, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019;3(23):3867–3897. doi:10.1182/bloodadvances.2019000916.
   PubMed Web of Science ®Google Scholar